Skip to main content

Table 3 Immunohistochemistry summary of HIV-1 negative and positive vulva cancer samples

From: Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana

Negative IHC-LANA LMP1 Cyc. D1 HPV16-E7 HPV16 E6 p21Waf1/Cip1 VEGF
1 - + + +++ + + -
2 - + + - + ++ +++
3 - + - - + - +
4 + + + + - + ++
5 + + ++ ++ - - ++
6 + + ++ ++ - - +++
7 - + + + + + +
8 + + + + + - +
9 - + + + - - +
Total 44% 100% 88% 77% 56% 44% 89%
Positive        
1 - - + - - - -
2 + + + + - + +
3 - - - - - - +
4 - + + + - + +
5 - - - + - + ++
6 + + + ++ + ++ +
7 - - - - - - +
8 + + - + + + ++
9 + + + ++ + ++ ++
10 + + - + + + +
11 + + + +++ - +++ ++
12 + + + + - + ++
13 + + - + - + ++
Total 61% 69% 54% 77% 31% 77% 92%
OR 1.99 0.01 0.16 1.0 0.35 4.26 1.42
CI 1.13-3.49 0.01-0.18 0.07-0.32 0.51-1.93 0.19-0.63 2.31-7.84 0.54-3.6
P value 0.01 0.001 <0.01 1.00 0.004 <0.001 0.47
  1. Oncogenic viruses identified in each VSCC patient as determined by Immunohistochemistry analysis. Most cases tested positive for KSHV, EBV, Cyclin D1, HPV16-E7, HPV16-E6, p21, and VEGF.